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ABSTRACT
Existing large gene expression data repositories
hold enormous potential to elucidate disease mech-
anisms, characterize changes in cellular pathways,
and to stratify patients based on molecular pro-
files. To achieve this goal, integrative resources
and tools are needed that allow comparison of re-
sults across datasets and data types. We propose
an intuitive approach for data-driven stratifications
of molecular profiles and benchmark our methodol-
ogy using the dimensionality reduction algorithm t-
distributed stochastic neighbor embedding (t-SNE)
with multi-study and multi-platform data on hema-
tological malignancies. Our approach enables as-
sessing the contribution of biological versus tech-
nical variation to sample clustering, direct incorpo-
ration of additional datasets to the same low dimen-
sional representation, comparison of molecular dis-
ease subtypes identified from separate t-SNE rep-
resentations, and characterization of the obtained
clusters based on pathway databases and additional
data. In this manner, we performed an integrative
analysis across multi-omics acute myeloid leukemia
studies. Our approach indicated new molecular sub-
types with differential survival and drug responsive-
ness among samples lacking fusion genes, includ-
ing a novel myelodysplastic syndrome-like cluster
and a cluster characterized with CEBPA mutations
and differential activity of the S-adenosylmethionine-
dependent DNA methylation pathway. In summary,
integration across multiple studies can help to iden-
tify novel molecular disease subtypes and generate
insight into disease biology.
INTRODUCTION
Gene expression profiling represents the most common
genome-wide method for studying cells in healthy and dis-
eased states. As a result, large repositories for data shar-
ing across studies exist (1–3). However, in practice a ma-
jor limitation to utilize these results in integrative analysis
is that technical differences, rather than separation based
on biological subtypes, tend to overshadow the comparison
of sample molecular characteristics (4,5). In particular, this
poses a challenge to characterize rare disease or rare sub-
types, as combining several datasets would be necessary to
obtain sufficient sample size for further analyses.
One common approach to discover different cellular
states and disease types based on gene expression is to use
unsupervised methods that require no prior knowledge on
sample groups within a dataset (6). Dimensionality reduc-
tion (7) and clustering represent data-driven methods that
are well-suited for discovery of sample grouping from com-
plex high-dimensional gene expression data and that are
typically used in combination, to mitigate the effect of the
curse of dimensionality (8). In context of data generated by
multiple laboratories, the contribution of technical varia-
tion to the obtained sample grouping remains a challenge
(4). Moreover, including additional studies and data types
into the analysis is important to evaluate robustness of the
analysis and to gain deeper insight into the biological mech-
anisms that underlie the distinct gene expression clusters.
Therefore, it would be desirable that new data can be inter-
preted in context of already carefully analyzed results. Yet,
adding new samples to unsupervised analysis typically suf-
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fers from the limitation that the lower dimensional visual-
ization and clustering will become different once more sam-
ples are included. One approach to overcome this limitation
is to identify gene sets that define specific clusters or signa-
tures discovered in the original analysis (9). However, this
scoring is typically calculated for a set of samples as a rela-
tive measure of gene set activity (10).
Acute myeloid leukemia (AML) multi-omics profiling
(11) represents one of the first efforts carried out to jointly
analyze several data types, including changes in DNA,
RNA expression levels and epigenetics in cancer. Recently,
similar multi-omics AML data was made available in com-
bination with drug responses (12). Efforts are ongoing to
expand this approach to other hematologic malignancies,
many of which are rare on population level. Therefore, inte-
grating different studies for investigating how the identified
molecular subtypes compare and relate to survival, or like-
lihood to respond to different treatments is important.
We propose here a framework aimed to identify and over-
come key challenges in analysis of multi-study and multi-
platform data and benchmark the methodology with inte-
grative analysis of hematologic malignancies.
METHODS
Workflow for integrating different gene expression studies
We exemplify the analysis of data originating from differ-
ent studies using a dataset of 9,544 gene expression pro-
files from the Gene Expression Omnibus (GEO) database
(1), comprising patient samples representing different can-
cers and proliferative disorders of hematopoietic lineage
origin, cell lines and normal blood cell types. We refer to
this sample set as Hemap in the following text. The curated
sample annotations and disease categories are available at
http://hemap.uta.fi. These data represent microarray data
from the commonly used hgu133Plus2 platform that were
jointly processed using a typical data analysis pipeline, in-
cluding theRMAprobe summarization algorithm (13) with
probe mapping to Entrez Gene IDs (from BrainArray ver-
sion 18.0.0, ENTREZG) to generate gene expression sig-
nal levels and a bias-correction method (5) developed for
clinical microarray data to correct for technical differences
between studies. To define new molecular subtypes in an
unbiased manner, dimensionality reduction was combined
with clustering. Initial comparison of the different dimen-
sionality reduction methods encouraged the selection of
t-SNE method, specifically the Barnes-Hut approximated
version of t-SNE implementation (BH-SNE) (14) to serve as
a benchmark scenario for data-driven exploration of disease
subtypes. For clustering the data following the dimensional-
ity reduction, we chose the kernel density-based algorithm
known as mean-shift clustering (15) (LPCM-package in R).
The bandwidth parameter was set to 1.5 (subsets of data,
one cancer type) or 2.5 (all data). This method allows the
discovery of sample sets which share similar features with-
out having to pre-specify the number of clusters. The term
‘cluster’ is used in the text to refer to this computational
clustering result, and the term ‘group’ is used in context of
visual examination.
Pre-processing of additional datasets
From the same microarray platform, 98 biological replicate
samples from studies included to Hemap, and 108 samples
from an independent study GSE49032 (16) were left out
from initial data processing and used as validation data (re-
fer to Supplementary Table S1). These data were normal-
ized as similar as possible to that applied to the original
data. Ideally, RMA summarization (13) and bias correction
(5) of new samples should be performed together with the
original samples. However, considering the dimensions of
the original data (9,544 samples), co-normalization of new
and old samples is not convenient from the viewpoint of
memory usage and computational complexity. In addition,
regeneration of the full data matrix would also require re-
running all the downstream analysis to maintain the con-
sistency of the results. Rather, we revised the pre-processing
approach that allows normalization of new samples to the
space of original data. The background correction step of
RMA was performed in a standard way as it requires no
inter-sample information. The quantile-normalization step,
however, utilizes information across all samples. Therefore,
we used the normalized distribution from the original data
to ensure that data distributions for novel samples do not
differ from those of the original ones. In the median pol-
ish summarization, the row (probe) effect of the original
data was used instead of calculating it across the novel sam-
ples. In the bias correction step of novel samples, the coef-
ficients describing the dependency between the bias metrics
and gene expressions were obtained from the original data
set. It should be noted that all the samples to be normalized
should also meet the quality control requirements that were
used with the original data set.
A microarray dataset (17) from a different array plat-
form (hgu133a+b) and RNA-seq data from the The Can-
cer Genome Atlas (TCGA) (11) and BeatAML (12) stud-
ies were included to benchmark robustness in discovery of
molecular subtypes and addition of samples from different
measurement platforms.Data fromhgu133a and b platform
(17) was normalized using RMA with probe mapping to
Entrez gene IDs as above. The TCGA RNA-seq data (11)
was obtained through cghub and realigned to hg19 genome
using Tophat2 (18) version 2.0.12 with default parameters.
The expression of genes included in the microarray was cal-
culated by counting the reads aligning to the correspond-
ing probe regions. RNA-seq data were further processed by
log2 transformation. The count matrix for the BeatAML
RNA-seq study was obtained from the authors. Genes with
expression > 1 cpm in more than 1% of samples were kept
and data was normalized using limma voom and quantile
normalization.
Quantitative metrics for assessing dimensionality reduction
and clustering results
Existing metrics for evaluating dimensionality reduction re-
sults include trustworthiness and continuity (19), analo-
gous to precision and recall in classification. Trustworthi-
ness measures whether data points appearing similar (prox-
imate) in the lower dimensional visualization should be
trusted to be similar in actuality, while continuity can be
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used to assess whether all original proximities ideally would
become visualized close-by.
To account for both biological and technical differences
that are characteristic of sample sets generated by different
studies, we propose new metrics based on normalized mu-
tual information (20) (NMI) to guide the feature selection
for dimensionality reduction in context of such heteroge-
neous data. NMI is defined as MI(X,Y) / ((H(X) + H(Y)) /
2), whereMI=mutual information, H= Shannon entropy.
X and Y correspond to cluster and class label vectors, re-
spectively. Empirical probability to observe a specific label
or cluster was used in calculating MI and entropy.
pNMI: This metric was calculated to assess how well the
obtained sample clustering (X) can distinguish known bi-
ological subtypes (Y, phenotypes) based on NMI between
cluster assignment and class labels (maximized).
eNMI: Similar as above, NMI was calculated between clus-
ter (X) and experiment (Y, data series) identifiers. The data
series differences represent mainly technical (not biologi-
cal) differences between samples and therefore this mea-
sure was minimized.
cNMI: In general, we would like to maximize the separa-
tion by phenotype (pNMI) and at the same time minimize
the separation by data series (eNMI). We combine these
two metrics to one by (pNMI + (1 - eNMI)) / 2. Higher
values of cNMI indicate better biological separation com-
pared to technical separation and thus this measure was
maximized.
The utility of the new metrics was demonstrated by com-
paring the parameters for t-SNE that uses by default Prin-
cipal Component Analysis (PCA) (21) for initial reduction
of features. We compared this setting to selection of genes
based on variance, or their combination. Selecting of 20 to
200 principal components (PCs), 2.5 to 100% of the most
variable genes were tested. As another alternative, PCA and
clustering based on k-means algorithm were used.
Remapping of samples to the t-SNE maps
New samples were mapped to an existing t-SNE space by
using a modified version of the BH-SNE (14) implemen-
tation. The embeddings for existing samples were given as
an additional input (the original algorithm would initial-
ize them by sampling from a Gaussian distribution). These
embeddings were kept locked throughout the run of the
gradient-descent optimizer, while the embeddings for new
samples were computed in parallel and independently of
each other. In this manner, embeddings of new samples do
not affect each other or the embeddings of locked sam-
ples, thus preserving the structure of the established t-SNE
map. The parameter theta that is related to the distance ap-
proximation was set to 0.3 instead of the default 0.5. To
remap samples that could come fromdifferentmeasurement
platforms, Euclidean distance was replaced by correlation
as a distance measure during remapping (one minus Pear-
son correlation between samples). The t-SNE method min-
imizes the divergence between two distributions: a distribu-
tion that measures pairwise similarities between the original
data objects (by default Euclidean distance) and a distri-
bution that measures pairwise similarities between the cor-
responding points in the embedding. By using a distance
metric based on correlation, the similarities between RNA-
seq samples and different microarray samples could be es-
timated without further transformations or normalizations
of RNA-seq data.
Evaluation of the remapping approach
To assign the new samples into existing clusters, distance
to the closest centroid was used in cluster assignment. The
cluster annotation was determined based on majority vot-
ing (forHemapAML,we utilized here the subset of samples
with RNA-seq counterpart that had most uniform annota-
tions across patients). Accuracy was calculated based on the
proportion of correct phenotype assignments based on clin-
ical annotation data. In the in silico experiments, a subset of
samples assigned to specific clusters were removed and then
re-mapped. In this case, the original cluster assignments
were used as class labels. The 15% most variable genes, t-
SNE map and mean-shift clustering were re-calculated for
each sample subset, in order to simulate situations when the
original sample set represented themolecular subtype (clus-
ter) well, or poorly.
To compare remapping success to a supervised approach,
a random forest classifier was trained using 15% most vari-
able genes (randomForestR-package version 4.6–14) by set-
ting the number of trees grown to 20000 while the rest of
the parameters were left unchanged. Remapped (removed)
samples were used as test data and prediction accuracy was
measured. Notice that the labels for training and test data
were obtained from clusters found from the full dataset (un-
like for re-mapping simulation), and only the 15% most
variable genes was re-calculated for each subset to train the
classifier.
Correspondence between t-SNE-map clusters
Similarity in sample clustering between t-SNE maps was
evaluated in a data-driven manner using gene set variation
analysis (GSVA) (10) enrichment scores. Two gene sets (20
top ranked positively or negatively correlated genes, sepa-
rately) were defined for each t-SNE map cluster based on
significant Pearson correlation (P-value < 0.05) of gene ex-
pression level and a given cluster label to assess the robust-
ness of the clustering and correspondence between t-SNE
maps.
Gene set analysis
The gene lists for the characterization of sample clus-
ters were obtained from MsigDB v5.0 (9), Wikipathways
(06.2015) (22), Recon 1 (23), Pathway Commons 7 (24) and
DSigDB v1.0 (25). Gene sets were limited to contain be-
tween 5 to 500 expressed genes per gene set, resulting in
19,680 gene sets that were evaluated across the dataset. In
addition, gene sets were defined on basis of significant clus-
ter correlation. The gene set variation analysis (GSVA) (10),
available in the R/Bioconductor packageGSVA 1.13.0, was
used to assign a gene set enrichment score (positive for in-
creased and negative for decreased expression) in a sample-
wise manner with the following settings: mx.diff = F, tau =
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0.25, rnaseq= T if RNA-seq, otherwise rnaseq= F. Empir-
icalP-value was computed using 1000 random permutation
of genes within the gene set. Estimation of significance was
limited to a range of gene set sizes (5–20, 25, 30, 40, 50,
75, 100, 200, 300, 400, 500) to adequately account for dif-
ferences in gene set size distribution. The observed pathway
scorewas comparedwith the randompermutations of a cor-
responding gene set size and empirical P-value computed
as the number of higher/lower scores in the permuted set
divided by the total number of permutations. Enrichment
of significant scores in a specific cluster was computed us-
ing a hypergeometric test. For separate t-SNEmaps, consis-
tent enrichment results were obtained by requiring the same
directionality in the correlation (to corresponding cluster)
with a nominal P-value < 0.05 for the smaller data set and
adjusted P-values < 0.001 for the larger dataset.
Characterization of sample clusters based on TCGA and
BeatAML multi-omics features
Categorical or binary annotation features (including clini-
cal variables), continuous/discrete numeric expression val-
ues and continuous/discrete numericmolecular data (muta-
tion, CNV and chromosomal translocation) were collected
for each sample.Missing values weremarked asNA. Each t-
SNE map cluster and combinations of clusters (binary fea-
ture) was tested against all other features and the statistical
significance evaluated using Spearman correlation between
a binary cluster feature and a numeric feature. With binary-
binary pairs Fisher’s exact test was used. Multiple hypoth-
esis testing correction was performed using the Benjamini-
Hochberg (BH) method.
For BeatAML (12) drug analysis, 25 drugs with lower
quartile of IC50 value below 10 nm were excluded as these
drugs have limited efficacy. Also Flavopiridol (positive con-
trol) was excluded, resulting in 96 drugs used in the anal-
ysis. One-way Anova was used to find drugs with a differ-
ential response between disease subtypes. Multiple hypoth-
esis testing correction was performed using the Bonferroni
method.
Myelodysplastic syndrome (MDS) signature was gener-
ated using Hemap dataset by identifying genes that were
most specific to MDS (hypergeometric test adjusted -log10
P-value> 100) resulting in 151 genes (Supplementary Table
S4). An additional filtered list was created based on differ-
ential expression between prior MDS versus noMDS clini-
cal annotation in BeatAML data (Wilcoxon rank sum test,
BH adjusted P-value<0.05). Both gene sets were evaluated
using GSEA in the TCGA cluster 4 matched AML sam-
ples versus remaining AML samples in all three datasets
(TCGA, BeatAML and Hemap AML).
Kaplan-Meier survival analysis
Survival time and status for each TCGA AML sample was
obtained from the supplementary table from the original
publication (11) (‘Patient Clinical Data’ dated 3.31.12). The
R package ‘survival’ was used to compute Univariate Ka-
plan Meier curves for each TCGA cluster and to calculate
the log-rank test.
Discretizing methylation signal levels with mixture models
Gaussian finite mixture models were fitted by expectation-
maximization algorithm provided in the R package mclust
(26) (version 4.3) to identify whether the value obtained
for a given methylation probe belonged to the signal (ex-
pressed) or noise distribution in each sample. The model
was chosen by fitting both equal and variable variancemod-
els and ultimately choosing the model which achieved a
higher Bayesian Information Criterion (BIC) to avoid over-
fitting. Amodel with three components was fitted by choos-
ing either an equal or unequal variance model according to
BIC. After model fitting, the percentages of measurements
belonging to each component were calculated for each sam-
ple. The portions of highly methylated regions in the stud-
ied cluster were compared against the rest of the samples by
calculating the Mann-Whitney U test.
Code availability
All custom code for analysis are accessible via GitHub
https://github.com/systemsgenomics/t-sne.cancermaps.
For step-by-step instructions and normalized data matrices
(RData files) to reproduce the analysis presented, refer to
the User Guide (see Supplementary Material).
RESULTS
Framework for multi-study integrative analysis
To develop robust data integrative solutions, we selected a
microarray dataset that was collected across several gene
expression studies profiling different hematologic malig-
nancies (referred to as Hemap dataset, see Methods). The
dataset was jointly processed using a typical data analysis
pipeline that included established normalization (13) and
batch effect correction (5) steps in data pre-processing, fol-
lowed by dimensionality reduction using the t-SNEmethod
that has been successfully applied in context of both simu-
lated and real datasets (14,27), and finally a clustering step
(15,28) to define disease subtypes in a data-driven manner.
Our framework, depicted in Figure 1, includes new quan-
titative metrics to guide the choice of analysis parameters
to minimize batch effects that arise from different labora-
tory protocols, allows incorporation of additional samples
to lower dimensional representations obtained with t-SNE
(27) and utilizes gene-set based integration between multi-
omics studies and platforms.
Assessing the contribution of technical variation in sample
separation
A fundamental challenge for joint analysis of the genome-
wide data available in public repositories is the technical
variability between data generated by different laboratories.
This challenge is exemplified by the application of t-SNE
across the heterogeneous data, with the subset of Hemap
AML samples: Upon iterative addition of experiments, as
shown in Figure 2A, analysis using the default PCA pre-
processing step results in separation of the data based on
the study rather than biological class (Figure 2A, PCA BH-
SNE). Testing alternative solutions (seeMethods), we found
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Figure 1. Data integrative analysis workflow. The schematic illustration depicts a typical data-driven analysis workflow and the data integrative approach
for multi-study and multi-platform datasets developed here. NMI (Normalized Mutual Information) optimization is used to find an optimal trade-off
between biological and technical differences for multi-study data. New data can be added to the same sample stratification based on remapping (applicable
to t-SNE maps) or by matching clusters obtained in separate analysis using gene sets.
that selection of genes based on variable expression results
in a much better sample grouping that does not reflect data
origin (Figure 2A, Variable genes BH-SNE). The technical
bias in the PCABH-SNE result, was not apparent based on
two common metrics, continuity and trustworthiness (19)
(PCABH-SNE0.92 and 0.96; Variable genes BH-SNE0.95,
0.97, respectively). To address this issue, we defined new
quality measures for quantitative evaluation of the sample
clustering in context of heterogeneous datasets: pNMI that
captures the separation of phenotypes (maximized), and
eNMI that can be used to penalize the separation of data by
experiment (minimized) (see Methods). The calculation of
these metrics (or the combined metric, cNMI) requires that
at least some samples have an annotated class and that ori-
gin (study/experiment identifier) of the samples is known.
Using these metrics, the effect of different analysis choices,
such as choosing different number of principal components,
or different percentage of genes could be systematically as-
sessed for the AML subset and the full sample collection,
as illustrated in Figure 2B (see also Supplementary Figure
S1). In both cases, feature selection based on genes with
highest variance performed favorably, reducing the techni-
cal biases (notice that the pNMI values between AML and
all Hemap samples are not directly comparable since clin-
ical subtype information was used for AML, whereas for
all samples pNMI was defined based on the main disease
type). This motivated the selection of 15% most variable
genes for t-SNE analysis in this study. However, the same
approach could also be used to test whether the observed
technical effects could be diminished for example by ad-
ditional or alternative pre-processing steps (Figure 1). The
annotated sample category is visualized in Figure 2C–E on
t-SNE maps generated based on most variable genes (see
also Supplementary Table S2), including two other sam-
ple subsets (acute lymphoblastic leukemia (ALL) and lym-
phomas). In each map, a sample grouping driven by cancer
subtypes was obtained. Therefore, the quantitative assess-
ment based on the new metrics can guide parameter selec-
tion for unsupervised sample stratification methods to mit-
igate technical variation effects.
Incorporation of additional datasets to predetermined t-SNE
space
Next, we developed a remapping algorithm that allows ad-
ditional samples to be included to the existing map. In this
manner, the obtained clustering of disease (sub-)types on
the t-SNE maps could be used to characterize new sam-
ples. Since many new studies currently use RNA-seq, the
remapping algorithm was extended to incorporate alterna-
tive types of data by revising the similaritymetric (seeMeth-
ods). As a first benchmark, the left-out samples (N = 10
from AML, and in total N = 98 Hemap samples) were all
assigned to the same cluster as their replicates, as shown
on the Hemap AML t-SNE map in Figure 3A in diamond
shapes (see also Supplementary Table S3 and Figure S2 that
shows the successful association of all 98 validation sam-
ples with the disease-of-origin). Secondly, re-mapping an in-
dependent microarray dataset to the ALL t-SNE-map suc-
cessfully assigned the clinical subtype for 95% of samples
(Figure 3B). Next, RNA-seq samples were analyzed from
the TCGA AML study. For 79 cases (from 162), a cor-
responding microarray sample exists in the Hemap AML
sample set. Remapping success was first evaluated by com-
paring the cluster assignments between the microarray and
RNA-seq sample pairs: 81%were assigned to the same clus-
ter center.We then considered the remainingRNA-seq sam-
ples. Of these patient RNA profiles, 97% were placed to a
cluster matching the annotated category. Remapping suc-
cess for all TCGAAML samples is shown in Figure 3A and
Supplementary Table S3.
For remapping to succeed, the initial dataset should be
representative of the biological heterogeneity in the disease.
Therefore, as a final benchmark we evaluated how robust
our method was in situations where a subtype was poorly
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Figure 2. Assessing the contribution of technical variation in sample clustering. (A) Iterative addition of AML data series to the sample set used for t-SNE
is shown. Each dot represents one sample and colors correspond to study that generated the data. The difference between using the PCA pre-processing step
(above) or using 15% of most variable genes (below) is visualized from a succession of maps (a single data series, 2, 5 or all). (B) The metrics for separation
of phenotypes (pNMI, in blue), data series (eNMI, in red) and combined metric (cNMI, in violet) shown represent the mean of 100 permutations with
different seed selections. Standard deviation is shown in grey around the lines. Selecting a different number of principal components (PCs) is compared to
selecting a different percentage of variable genes using the full Hemap dataset and Hemap AML sample set. The fine structure on the t-SNE maps with
15% gene selection matches closely pre-B-ALL (C), AML (D) and BCL (E) clinical subtypes (in color).
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Figure 3. Remapping new samples to the t-SNEmap. (A) AMLmicroarray
validation samples thatwere left out (N= 10, diamonds) andTCGARNA-
seq samples (N = 162, triangles) re-mapped on the Hemap AML t-SNE
map. Notice that similar samples mapped in close proximity to each other
may overlap on the visualization. (B) Remapping result for samples from
an independent ALL study11 (GSE49032) to the Hemap ALL t-SNEmap.
The subtype of re-mapped samples is indicated in color in A and B.
represented in the initial dataset. To simulate this scenario,
samples from a specific cluster were iteratively removed. We
compared the well-separated AML cluster 14 (with PML-
RARA samples) and cluster 4 (including CEBPA-mutated
samples) that was more challenging to distinguish (see Sup-
plementary Figure S3 and Table S2). The re-mapping of
samples from cluster 14 achieved similar accuracy as super-
vised random forest classifier (seeMethods), even when only
10 samples were included in the initial data (accuracy 0.87),
while the accuracy for cluster 4 varied from 0.93 to 0.66.
In this case the supervised classifier trained with the orig-
inal clusters was more robust, however it should be noted
that the clusters were re-calculated from each subset only
for the re-mapping (Supplementary Figure S3). Finally, to
exemplify whether it would be possible to distinguish that
the subtype for the remapped sample is missing in the ini-
tial dataset, we included diagnostic plots on the correlation
scores across samples re-mapped with cluster-specific high,
median, and low correlation, and for the situation that the
cluster was completely missing (Supplementary Figure S4).
In conclusion, our re-mapping method readily extends t-
SNE results beyond the initial sample set when new samples
matching the represented biological subtypes are analyzed,
and shows robustness for different technologies and match-
ing underrepresented subtypes.
Comparison of data-driven stratifications of molecular dis-
ease subtypes
Comparisons between studies would allow to determine
whether the same molecular subtypes segregate in a repro-
ducible manner. Towards this end, we developed method-
ology for examining the correspondence between clusters
on separate t-SNE maps. We chose the TCGA AML (11)
(RNA-seq, Figure 4), Ross ALL (17) (microarray, Supple-
mentary Figure S5) and BeatAML (12) (RNA-seq, Supple-
mentary Figure S6) studies for comparative analysis. Fig-
ure 4A shows the generated t-SNE map for TCGA RNA-
seq samples, which resulted in seven distinct clusters (re-
ferred to as TCGA clusters 1–7). The comparison with an-
notated cytogenetic types was consistent; samples carrying
PML-RARA, RUNX1-RUNX1T1, CBFB-MYH or MLL
fusions segregated into distinct clusters. To identify match-
ing clusters from the Hemap AML t-SNE map, we devel-
oped a data-driven approach that defines and scores gene
sets for each cluster (see Methods, refer to Supplementary
Table S4 for TCGA cluster gene sets). The samples with sig-
nificant enrichment are colored on the Hemap AML t-SNE
map, and their enrichment score compared to annotations
as a heatmap (Figure 4B). Samples with matching fusion
gene status received the highest enrichment scores, allowing
matching of clusters between the maps (Supplementary Ta-
ble S5). The application to ALL (17) and BeatAML (12)
samples (Supplementary Figures S5 and S6, respectively)
showed similar robustness in discovery of matching sub-
types.
Integration with multi-omics profiles and pathway activity
analysis to characterize the discovered molecular subtypes
The classification of AML has traditionally distinguished
between fusion gene-positive categories (29,30). However,
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Figure 4. Evaluation of disease subtypes across datasets. Comparison of sample clustering on the t-SNE maps for TCGA AML RNA-seq samples (N
= 162) and Hemap AML is shown. (A) The data-driven cluster assignment (TCGA clusters 1–7) can be compared with sample molecular annotations
colored on the map and the heatmaps below. (B) Enrichment scores for TCGA cluster gene sets that matched samples with common fusion genes (clusters
1, 2, 6 and 7) are colored on the Hemap AML map (significant enrichment adj. P-value < 0.001 in red). The raw GSVA scores are shown below as a heat
map (red tones indicate high expression of the gene set and blue tones low expression).
additional clusters segregate in the TCGA and Hemap
AML t-SNEmaps that can be matched between the studies
(Supplementary Figures S7A–C, Table S5).NPM1,CEBPA
and RUNX1 mutations were characteristic for these non-
fusion samples in Hemap (Figure 5A). The distinction be-
tween the samples is clinically relevant, as the identified
clusters differed in overall survival (Figure 5B). Statistically
significant associations between the map clusters and dif-
ferent multi-omics features or pathway activity scores were
queried to further characterize the discovered molecular
subtypes (seeMethods). Based on correlation of cluster as-
signment with multi-omics TCGA data (11), NPM1 mu-
tations were associated with two clusters (TCGA clusters
3 and 6), whereas CEBPA mutations characterized TCGA
cluster 5 (Figure 5C). The distinction between these two
NPM1 positive clusters was associated with the cellular
morphology (FAB type in Figure 5C). In addition, our
analysis revealed a subgroup (TCGA cluster 4 and corre-
sponding Hemap samples indicated in Supplementary Fig-
ure S7D) with several cases positive for either TP53 or
RUNX1mutations and/or complex karyotypes (Figure 5A
and C).
Next, we detected significant associations between the
cluster category and pathway activity. The gene set enrich-
ment analysis (seeMethods) confirmed that the TCGA and
Hemap patients from the matched clusters share molecu-
lar characteristics (Supplementary Table S5). The TCGA
cluster 5 (CEBPA mutated, Figure 5C) and its corre-
sponding cluster on the Hemap AML map (refer to Fig-
ure 5A and Supplementary Figure S4B) were significantly
associated with S-adenosylmethionine (SAM)-dependent
methyltransferase activity (Figure 5D, hypergeometric test
adjusted P-values 5.6e-05 and 1.5e-26, respectively). Be-
cause all DNA methyltransferases use SAM, we quanti-
fied TCGA DNA methylation data to test whether global
changes in methylation patterns exist between clusters (see
Methods). Accordingly, we observed a significant elevation
in DNAmethylation level in the TCGA cluster 5 compared
to other samples (Figure 5E, Mann-Whitney U-test P =
2.681e-06).
Corresponding genetic and clinical features characteriz-
ing the AML molecular subtypes could be robustly identi-
fied also from BeatAML data (Figure 5F). In comparison,
mutations in IDH1/2, TET2, NRAS and KRAS were sig-
nificantly enriched in several subtypes, but not subtype spe-
cific (Supplementary Figure S7E). TCGA cluster 4matched
in BeatAML data a cluster where several cases had prior
MDS clinical status and a secondary disease. Accordingly,
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Figure 5. Multilevel data integration reveals AML molecular subtypes with distinct mutation and epigenetic phenotypes. (A) Mutational status for most
significantly cluster-associated mutations is indicated in color on the Hemap AML map. (B) The survival analysis of Hemap patients comparing the
subtypes matched with the TCGA map are shown as Kaplan-Meier plots. (C) Heatmap of significant genetic and clinical associations (Fisher´s exact test
or correlation test of significance adj. P-value<0.05) for each subtype is shown. (D) Significant enrichment (adj. P-value < 0.05) for SAM-dependent
methyltransferase activity is shown on the Hemap AML t-SNE map. (E) The percentage of regions assigned to the high methylation state is visualized
as box plots comparing TCGA cluster 5 patients (N = 20) and rest of TCGA AML clusters (Mann-Whitney U-test P-value is indicated). (F) Significant
associations (Fisher´s exact test or correlation test of significance adj. P-value<0.01) for BeatAML samples matching TCGA clusters are shown as in C.
(G) The median drug AUC values per cluster from BeatAML ex-vivo drug screening are shown as a heatmap for drugs with differential sensitivity across
AML molecular subtypes (One-way Anova, adj. P-value<0.05). H. Drug AUC values for MK 2206 (Akt inhibitor), Tozasertib (Aurora kinase inhibitor)
and Sunitinib (FLT3 inhibitor) are shown as boxplot for normal karyotype clusters 3,4,5 and cluster 6 also containing FLT-mutation positive samples.
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an MDS gene expression signature (built using MDS sam-
ples in Hemap) was enriched in samples associated with this
cluster in all data sets (Figure 5F and Supplementary Figure
S7F–H).
Encouraged by the robustness of our subtype charac-
teristics across data sets, we examined the drug response
AUC values available for the BeatAML samples. In total
28 drugs were differentially sensitive (one-way Anova test,
adjusted P-value<0.05) (Figure 5G) comparing the discov-
ered AML subtypes. Samples matched to TCGA cluster 3,
with high blast count (Figure 5C and F), were sensitive to
most drugs. However, samples matched to each of the non-
fusion TCGA clusters (3, 4 and 5) were resistant to MK
2206 (AKT inhibitor) (Figure 5H). In comparison TCGA
cluster 6 that resembled cluster 3 based on mutations (Fig-
ure 5C and F) but had a more differentiated cell phenotype
was associated with cases that were sensitive (Figure 5H),
further supported by various AKT pathway signatures that
were enriched in this cluster (Supplementary Table S5). The
Aurora kinase inhibitor Tozasertib and the FLT3 inhibitor
Sunitinib were effective in cases matched to TCGA cluster
3, while cases matching clusters 4 and 5 were resistant to all
FLT inhibitors tested (Figure 5H).
DISCUSSION
A large number of biological conditions have been charac-
terized at genome-wide level since the introduction of mi-
croarray and deep sequencing technology (1–3), However,
most of the studies include only tens to hundreds of sam-
ples. Cancers of hematopoietic origin serve as an impor-
tant example where data integration is essential from the
sample availability perspective, since many of these cancers
are rare on the population level (30,31). Therefore, under-
standing the complete heterogeneity and similarity of dis-
ease states and their subtypes requires integrative data anal-
ysis methodology. Here, we tested solutions that allow dis-
tinguishing sample separation driven by technical variation,
evaluating the robustness of the obtained biological strati-
fications between studies and inclusion of new sample sets
and data types to pre-existing analysis results. We demon-
strated the relevance of our approach to generate insight
into disease biology and to identify potential novel molec-
ular disease subtypes by performing an integrative analysis
across three large AML studies.
Currently, it is relatively easy to compile multi-study
datasets by prioritizing relevant data sets based on gene-
level queries (32). However, removing technical variation,
or batch effects, from data before downstream analysis is
a vital part of studies analyzing such datasets generated
from different experiments (4,5,33). Failure to identify and
remove unwanted technical variation may lead to an in-
creased amount of false positive findings (34). We propose
here new NMI metrics to guide the choice among alterna-
tive methods and settings to achieve minimal loss of bio-
logically relevant gene information (high separation of phe-
notypes) while reducing the technical variation enough not
to interfere with the biological interpretation of the results.
While the value range of the NMI metrics is different for
each dataset, observing eNMI values above pNMI can serve
as a general indicator that technical differences may over-
whelm the biological differences in the sample stratification
obtained. The NMI metrics extend to more than just mi-
croarray and RNA-seq data presented here, to scenarios
where sample clustering is relevant. For example, in con-
text of single-cell RNA-seq the challenge of batch effects
has been recognized (35), and new data sets are becoming
increasingly available.
Motivated by recent advances in unsupervised applica-
tions, we selected the t-SNE algorithm for further devel-
opment, with the aim to provide solutions suitable for het-
erogeneous data. Evaluating the dimensionality reduction
alone (continuity, trustworthiness (19)) was found insuffi-
cient to capture the technical bias in the t-SNEmaps. Based
on the NMI metrics, we found that removing less variable
genes prior to t-SNE or clustering could remedy the tech-
nical biases. Alternatively, additional pre-processing steps
or decomposing the variation could be attempted to re-
duce batch effects, including methods that attempt to re-
move the variation contained in top principal components
(36,37). To date, microarray repositories are still by far the
largest resource for molecular data and hold a vast poten-
tial for large-scale studies. Compared to existing transcrip-
tome collections (38,39), our goal was to develop methods
that can generalize the integrative analysis beyond the ini-
tial dataset. We showed that new samples can be added to
extend an existing t-SNE map. This could be relevant for
achieving compatibility of analysis against different refer-
ence dataset versions. Moreover, we demonstrated that in-
clusion of RNA-seq profiles for joint analysis with microar-
ray results was feasible in this manner. Secondly, we intro-
duce an alternative gene set-based integration across dif-
ferent AML datasets, using the unsupervised t-SNE pro-
jections of different studies as the initial starting point.
For remapping or defining cluster gene sets, the robustness
of the analysis is related to how representative the initial
dataset is of the biological context, such as the cancer sub-
types considered here. The overall correlation to samples
on the map and cluster-specificity of high correlation val-
ues can be used as indication of how reliably the sample can
be re-mapped. The enrichment results with GSVA are re-
lated to the sample composition, as genes are ranked based
on kernel estimation of the cumulative density function us-
ing all samples (10). Therefore, the re-mapping approach
would be better suited when comparing samples from small
or subtype-focused studies to a larger reference study.
Based on these data integrative solutions, we performed a
comprehensive analysis with integration of additional data
types from two multi-omics AML studies to further char-
acterize the identified sample groups. Our approach consid-
ers gene expression levels as the main phenotype that gene
set and pathway analysis can further characterize. Other
data types such as mutations and methylation levels were
included by correlating them with the clusters observed in
this phenotype (gene expression) space.Alternatively,multi-
view methods designed to preserve structures between sev-
eral layers of data could be utilized (40,41). While these
methods appear promising, in practice different data types
and result interpretation present challenges (41). Factor
analysis could represent an approach that generates better
interpretable data representations when sufficient number
of samples is available (42).
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Our analysis comparing data-driven identification of
AML molecular subtypes from TCGA, Hemap and Beat-
AML datasets revealed a distinct clustering of CEBPA,
NPM1, RUNX1 and TP53 mutation positive samples.
These molecular phenotypes that we found to distinguish
clusters of fusion gene-negative samples could be identified
from each dataset, demonstrating that the molecular sub-
types found are robust, comparable to the fusion gene clus-
ters distinguished in previous classifications (29,30). The
cluster with the worst survival in our analysis included sam-
ples that were characterized by complex karyotypes and
TP53 mutations, agreeing with recent genotyping data of
recurrent mutations (43). The enrichment of MDS-linked
mutations (TP53, RUNX1, ASXL1, and U2AF1), clinical
annotations of priorMDS status and theMDS-like gene ex-
pression signature indicate that MDS-like AML cases have
a unique molecular phenotype associated with poor sur-
vival. Furthermore, the analysis of cluster-associated muta-
tions distinguished a patient cluster withCEBPAmutations.
Using pathway analysis, we could demonstrate that TCGA
andHemap patients from thematched clusters had elevated
expression of genes involved in SAM-dependent methyla-
tion activity. Previous studies have found contradicting re-
sults, reporting both specific (11) or broad (44) methylation
changes. We validated that patients with high pathway ac-
tivity score had an elevated global DNA methylation level
using multi-omics TCGA data. Finally, we linked drug sen-
sitivities to this AML molecular subtype characterization.
In this manner, the integrative data analysis presented could
facilitate further characterization of drug resistance mech-
anisms.
In conclusion, we present new data integration ap-
proaches for multi-study and multi-omics datasets that al-
low researching disease subgroups across studies. In future,
this analysis framework can be adopted to support the uti-
lization of genome-wide data across different biological sys-
tems and disease contexts.
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